Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey

BACKGROUND: Since July 13, 2021, a third SARS-CoV-2 vaccine BNT162b2 was approved in Israel to immunocompromised and seniors 60 years of age or older. We aimed to evaluate vaccine's reactogenicity. METHODS: A retrospective cohort, using electronic surveys sent to booster vaccine recipients, dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro Ben David, Shirley, Shamir-Stein, Na’ama, Baruch Gez, Sharon, Lerner, Uri, Rahamim-Cohen, Daniella, Ekka Zohar, Anat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461972/
https://www.ncbi.nlm.nih.gov/pubmed/34571262
http://dx.doi.org/10.1016/j.clim.2021.108860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461972/
https://www.ncbi.nlm.nih.gov/pubmed/34571262
http://dx.doi.org/10.1016/j.clim.2021.108860

Ejemplares similares